ClinicalTrialsFinder

HER2 Overexpression Clinical Trials in New York, New York

1 recruitingNew York, New York

Showing 1–1 of 1 trials

Recruiting
Phase 1

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Non-small Cell Lung CancerHER2Advanced Solid Tumor, Adult+3 more
Cogent Biosciences, Inc.100 enrolled6 locationsNCT07361562